Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Circulatory System Drugs > TYRA-300 for Sale > Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - large image1
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image1
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image2
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image3
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image4
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image5
Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D buy - image6

Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D

COA TDS 149 Inquiries

Unit Price:

$1500-1800/G FOB

Get Latest Price
CAS No.:

2800223-30-5

Grade:

Pharmaceutical Grade

Content:

99.9%

Port:

Hangzhou

Brand:

HyperChem

Packaging:

1g/bag, 20g/bag, 50g/bags or other quantities

Price valid (until):

2028-01-31

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

  • Product Description

  • Seller Information

  • Inquiry History

  • Description
    Name Dabogratinib
    CAS number 2800223-30-5
    Synonym TYRA-300
    Dabogratinib
    2800223-30-5
    A1AV2
    dabogratinib
    Related APIs # Baricitinib - CAS: 1187594-09-7
    Tofacitinib - CAS : 477600-75-2
    Fedratinib - CAS : 936091-14-4
    Upadacitinib - CAS : 1310726-60-3
    Oclacitinib - CAS: 1208319-26-9
    Description Detailed Uses & Applications (Comprehensive Overview)

    Dabogratinib (TYRA-300) is an investigational, oral, small-molecule inhibitor specifically designed to target the fibroblast growth factor receptor 3 (FGFR3) with high selectivity over other FGFR isoforms (FGFR1, 2, 4). Its development is strategically focused on two distinct therapeutic areas where FGFR3 dysregulation plays a central pathogenic role: oncology (specifically urothelial cancers) and skeletal dysplasias (achondroplasia). The drug's value proposition lies in its FGFR3 isoform selectivity, which aims to provide clinical efficacy while minimizing the off-target toxicities (e.g., hyperphosphatemia, retinal detachment) commonly associated with first-generation pan-FGFR inhibitors.
    1. Oncology Application: FGFR3-Altered Urothelial Carcinoma
    In the oncology setting, TYRA-300 is being developed as a precision medicine for tumors harboring FGFR3 alterations​ (mutations or fusions), which are frequent drivers in urothelial carcinoma (bladder cancer). The primary mechanism here is antagonism of oncogenic signaling.

    Mechanism of Action in Cancer: In FGFR3-altered cancers, the receptor is constitutively active, leading to uncontrolled proliferation and survival of tumor cells. Dabogratinib binds to the ATP-binding pocket of FGFR3, inhibiting its kinase activity. This blockade suppresses downstream signaling pathways (MAPK, PI3K/AKT, STAT), resulting in cell cycle arrest and apoptosis (programmed cell death) in preclinical models. Its activity extends to certain gatekeeper mutations​ (e.g., FGFR3 V555M), which often confer resistance to other FGFR inhibitors, positioning it as a potential therapy for resistant disease.

    Clinical Context & Unmet Need: Approximately 15-20% of muscle-invasive and metastatic urothelial carcinomas harbor FGFR3 alterations. While Erdafitinib (a pan-FGFR inhibitor) is approved, its use is limited by toxicity from FGFR1 inhibition. TYRA-300's selectivity aims to offer a safer, more targeted option. It is under evaluation in multiple Phase 2 trials:
    SURF301: For metastatic urothelial carcinoma (mUC).
    SURF302: For FGFR3-altered, intermediate-risk, non-muscle invasive bladder cancer (NMIBC).
    SURF303: For low-grade upper tract urothelial carcinoma (UTUC).

    Therapeutic Goal: To provide a potent, well-tolerated oral treatment that can be used in the metastatic setting and potentially in earlier stages of disease to delay or prevent progression, improving progression-free survival (PFS) and quality of life.

    2. Rare Disease Application: Achondroplasia (Skeletal Dysplasia)
    In a groundbreaking repurposing of its mechanism, TYRA-300 is also being studied as a potential treatment for achondroplasia, the most common form of dwarfism. In this context, the drug's role is modulation of physiological bone growth​ rather than cytotoxicity.
    Mechanism of Action in Achondroplasia: Achondroplasia is caused by a gain-of-function mutation (G380R) in FGFR3. This hyperactive receptor acts as a negative regulator of endochondral bone growth​ at the growth plate, inhibiting chondrocyte proliferation and differentiation, leading to shortened long bones. Dabogratinib, by inhibiting the overactive FGFR3, aims to "release the brake"​ on bone growth. It seeks to restore a more normal pace of chondrogenesis, thereby increasing annual growth velocity and improving final adult height potential.

    3. Potential Broader Applications
    Preclinical data suggests potential utility in other FGFR3-driven skeletal dysplasias​ (e.g., hypochondroplasia, thanatophoric dysplasia) and other solid tumors where FGFR3 fusions are implicated (e.g., glioblastoma, squamous cell lung cancer), though these remain exploratory.
    Molecular Formula  C 25 H 24 Cl 2 N 6 O 3S
    Molecular Weight 559.47 g/mol
    Appearance White or almost white powder
    Quality Standard Enterprise standard; 99.99%
    Shipping Condition Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
    Storage Condition Dry, dark and at 0-28℃ for short term (days to weeks) or 0-8℃ for long term (months to years).
    Shelf Life >2 years if stored properly
    Sample package Double plastic bags inside, fiber drum outside, any quantity available.
    Commercial package Aluminium Tin, Fiber drum
    Origin China


    Shop USP Quality Standard API Finasteride Powder with CAS 98319-26-7-Detailed Image 2

    Shop USP Quality Standard API Finasteride Powder with CAS 98319-26-7-Detailed Image 3



    FAQ

    Q1. What is the Hyper chem payment term?
    T/T advance
    LC at sight
    DP at sight
    Trade assurance 
    Money gram 

     

    Q2. What is Hyper chem shipment policy?
    Our policy is to strive for the quickest shipment time possible, with ready stock sample shipment typically going out the same day that your order was placed. Your satisfaction is very important to us.
    For non-ready stock, please contact the Hyper Chem sales team to negotiate.

     

    Q3. What hyper chem will provide after shipment?
    For sample orders: 
    After shipment is done, an timely email including:

    Track details (Fedex /TNT/DHL/EMS Track number)

    Package photo

    COA, MSDS, etc 

    Dispatch date & Estimated arriving time

    Shipping invoice

    For commercial orders
    A full set of shipment documents as well as package photos can be provided
    in scan-copy and original, to help customers complete the customs clearance process.

     

    Q4. What is Hyper Chem shipment term?

    By Express   
    DHL  FedEx  TNT  EMS                               
    Fast:5 days around                             
    High cost, door to door service

    By Air                                         
    Suitable for more than 50kg 
    Fast :3-7 days Hight cost, port to port, professional broker needed 

    By Sea
    Suitable for more than 500kg      
    Slow:7-45 days, Low cost, port to port, professional broker needed 
    We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

     

    Q5. Does hyper chem provide a shipment return policy?
    Yes, we have.
    Return Policy: At Hyper chem, your satisfaction is guaranteed. If you are dissatisfied for any reason with a product, please send back the unused portion along with your packing slip and a brief note on why you were dissatisfied  within 45 days of purchase for a full refund to:

     

    Q6. What is hyper chem After-sales service
    •Documents support: COA ,MSDS, MOA ,MS Report,HNMR Report,SDS,DMF
    • Customer Support: Shipment clearance support, quality issue support
    • Automated Customer Service: Our worldwide customers enjoy immediate 24/7 access to the HYPER CHEM support team from any location, at any time.

     

     

     

    About HyperChem

    Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

     

    Among them, our key client industrial sectors around the global are:

     

    Pharmaceuticals
    Nutrition Ingredients/ Dietary supplements
    Cosmetic Ingredients
    Food Ingredients
    Veterinary API
    Agriculture fertilizer
    Custom Synthesis lab supply

     

    HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.

    ECHEMI Editorial Reference
    Dabogratinib(TYRA-300) , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations.

    Certificates

    Basic Info
    Product Name:

    TYRA-300

    Other Name:

    TYRA-300;2,6-Diazaspiro[3.3]heptane, 2-[5-[5-[(1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy]-1H-indazol-3-yl]-2-pyridinyl]-6-(methylsulfonyl)-;(R)-5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-3-(6-(6-(methylsulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-3-yl)-1H-indazole;TYRA-300(Dabogratinib);Tyra-300 99% Shaanxi Dideu Medichem

    CAS No.:

    2800223-30-5

    Molecular Formula:

    C25H24Cl2N6O3S

    InChIKeys:

    JOAFWIHZEBKYQK-OAHLLOKOSA-N

    Molecular Weight:

    559.47

    EC Number:

    610-261-8

    Characteristics
    Density:

    1.58±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

    Boiling Point:

    791.2±70.0 °C(predicted)

    PKA:

    11.87±0.40(predicted)

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

    Location:

    Rm. 803, Tower 4, LOFT49 Creative City Pioneer Zone, No.88 Jiru Rd. Gongshu Dist., Hangzhou, 310015 ZJ, China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    10

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    11-50

    Year of Establishment:

    2013

    Certifications:

    Certification Report by Bureau Veritas

    About HyperChem

    Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to meet the needs of a diverse range of pharmaceutical cosmetics ingredients and nootropic supplements companies worldwide.

    Our Competitiveness

    One-stop supply

    Wide Range Of products including pharmaceutical, Cosmetic Ingredients and nootropic supplements

    Among all the pharmaceuticals,

    90% of them with GMP certificates,

    85% of them with DMF files and

    50% of them passed FDA approval,

    30% get CEP certificate

    20% are new R&D products.

    Custom Repackaging Service


    We can efficiently repackage your material into sample sizes, custom batch-specific sizes, or semi-bulk package sizes according to your specifications. And ensures the product is packaged in a quality-controlled environment and will maintain its integrity throughout every stage of the process.

    Quality Control/Quality Assurance


    HyperChem is committed to delivering on its promises of top-quality products with verified quality data.

    All materials are vigorously inspected by the factory and/or outsourced analytical laboratories to ensure each and every lot meets or exceeds our reference standards.

    Trade assurance service with 100% payment protection, It is best achieved by delivering products and services 100% right the first time, on time, every time.

    Professional

    Transparent Communication

    Fast Reaction,

    Professional Suggestion

    Beyond Expectation.

    We have exclusive partnerships with research and production facilities across the country and we offer varied pharmaceutical services in the most cost-efficient way. The production facilities are GMP, WHO-GMP, EU GMP and US FDA approved and are backed by strong regulatory support such as Dossier, DMF, Tech Pack and relevant Stability studies for regulatory filings.

  • Inquiry History
    149 Inquiries
    Country Product Purchase Quantity Date Posted
    India

    Tyra-300 CAS 2800223-30-5

    9 G Jul 8, 2026
    United States

    TYRA-300 CAS 2800223-30-5

    8 G Jul 14, 2026
    United States

    High Quality TYRA-300 99% powder 2800223-30-5 Shaanxi Dideu Medichem Co.Ltd

    8 G Aug 2, 2026
    Germany

    TYRA-300

    5 G Aug 1, 2026
    Canada

    TYRA 300

    1 G Jun 2, 2026
    Mexico

    Tyra-300

    12 G Aug 24, 2026
    Germany

    Tyra-300

    0.5 G Aug 24, 2026
    Egypt

    Tyra-300

    10 G Aug 23, 2026
    United States

    tyra

    1 G Aug 22, 2026
    Brazil

    Dabogratinib

    2 G Aug 14, 2026
    Canada

    tyra-300

    1 KG Aug 10, 2026
    Canada

    tyra-300/dabogratinib

    1 G Aug 9, 2026
    Poland

    Tyra-300

    15 G Aug 5, 2026
    Germany

    Tyra 300

    2 G Aug 3, 2026
    United States

    Tyra-300

    25 MG Aug 2, 2026
    Australia

    dabogratinib

    1 KG Aug 1, 2026
    United States

    Anticancer API 99% TYRA-300/TYRA 300/Dabogratinib CAS:2800223-30-5 for R&D

    6 G Jul 25, 2026
    Germany

    Dabogratinib

    1 G Jul 23, 2026
    Lithuania

    TYRA-300

    100 G Jul 21, 2026
    Canada

    Tyra-300

    10 G Jul 20, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.